

# CITATION REPORT

List of articles citing

## The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

DOI: 10.1016/j.clinthera.2015.02.018  
Clinical Therapeutics, 2015, 37, 764-82.

**Source:** <https://exaly.com/paper-pdf/61258172/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
418	The Forecast Is Bright: Recent Advances in Melanoma Treatment. <b>2015</b> , 19, 435-9		
417	Immune Checkpoint Blockade in Hepatocellular Carcinoma. <b>2015</b> , 4, 201-7		36
416	The Evolution of Therapies in Non-Small Cell Lung Cancer. <b>2015</b> , 7, 1815-46		81
415	PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells. <b>2015</b> , 6, 1320-30		6
414	Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. <b>2015</b> , 5, 183		62
413	Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. <b>2015</b> , 2015, 308574		23
412	Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. <b>2015</b> , 51, 1435-43		52
411	Adolescent and young adult patients with cancer: a milieu of unique features. <b>2015</b> , 12, 465-80		69
410	The potential of tumor-derived exosomes for noninvasive cancer monitoring. <b>2015</b> , 15, 1293-310		92
409	Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. <b>2015</b> , 20, 1127-34		23
408	The Patient Protection and Affordable Care Act: politics and pills. <i>Clinical Therapeutics</i> , <b>2015</b> , 37, 687-9	3.5	
407	Immune checkpoint inhibitors in the treatment of metastatic melanoma. <i>Clinical Therapeutics</i> , <b>2015</b> , 37, 753-4	3.5	4
406	Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. <b>2015</b> , 23, 2341-2348		267
405	Immunopharmacogenomics. <b>2015</b> ,		3
404	Primary Melanoma of the Oral Mucosa: A Case Report and Review of Literature. <b>2016</b> , 06,		
403	Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. <b>2016</b> , 7, 32318-28		105
402	Nanodelivery of Anticancer Agents in Melanoma: Encouraging, But a Long Way to Go. <b>2016</b> , 189-201		1

401	[Understanding current therapies in metastatic melanoma]. <b>2016</b> , 144, 1448-1458	
400	Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination. <b>2016</b> , 7, 577	15
399	A Perspective of Immunotherapy for Prostate Cancer. <b>2016</b> , 8,	21
398	Development of a Modular Assay for Detailed Immunophenotyping of Peripheral Human Whole Blood Samples by Multicolor Flow Cytometry. <b>2016</b> , 17,	49
397	Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. <b>2016</b> , 2016,	51
396	End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based study. <b>2016</b> , 175, 583-92	13
395	Filling the Tank: Keeping Antitumor T Cells Metabolically Fit for the Long Haul. <b>2016</b> , 4, 1001-1006	18
394	A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses. <b>2016</b> , 5, e83	38
393	Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8+ T cells. <b>2016</b> , 35, 699-708	48
392	The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines. <b>2016</b> , 95, e3134	12
391	Development of amino- and dimethylcarbamate-substituted resorcinol as programmed cell death-1 (PD-1) inhibitor. <b>2016</b> , 88, 50-8	11
390	Keratoacanthoma-appearing melanoma metastases in a patient receiving pembrolizumab therapy. <b>2016</b> , 2, 247-9	0
389	PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. <b>2016</b> , 5, e1235107	77
388	PD-1/PD-L1, Only a Piece of the Puzzle. <b>2016</b> , 140, 1187-1188	7
387	Pembrolizumab in classical Hodgkin lymphoma. <b>2016</b> , 97, 219-27	16
386	Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. <b>2016</b> , 107, 107-15	22
385	Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells. <b>2016</b> , 49, 1099-107	15
384	Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial. <b>2016</b> , 65, 1395-1400	15

383	Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis. <b>2016</b> , 11, 753-761	45
382	Dephosphorylation of the adaptor LAT and phospholipase C- $\beta$ by SHP-1 inhibits natural killer cell cytotoxicity. <b>2016</b> , 9, ra54	33
381	Development of an autologous canine cancer vaccine system for resectable malignant tumors in dogs. <b>2016</b> , 182, 95-100	10
380	Recent Trends in the Management of Hepatocellular Carcinoma with Special Emphasis on Treatment with Regorafenib and Immune Checkpoint Inhibitors. <b>2016</b> , 34, 714-730	7
379	Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside. <b>2016</b> , 25, 831-838	30
378	Molecular Markers and Targeted Therapeutics in Metastatic Tumors of the Spine: Changing the Treatment Paradigms. <b>2016</b> , 41 Suppl 20, S218-S223	24
377	Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases. <b>2016</b> , 175, 1382-1386	90
376	NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells. <b>2016</b> , 197, 953-61	62
375	Introduction: Natural product-based drug discovery in Immunopharmacology. <b>2016</b> , 37, 1-2	2
374	A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2. <b>2016</b> , 65, 383-92	26
373	Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis. <b>2016</b> , 9, 32-40	13
372	Prognostic significance of PD-L1 and PD-L2 in breast cancer. <b>2016</b> , 47, 78-84	154
371	Immunotherapy for Resected Pulmonary Metastases. <b>2016</b> , 26, 69-78	2
370	Clinical implications of basic research in hepatocellular carcinoma. <b>2016</b> , 64, 736-45	31
369	Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. <b>2016</b> , 19, 82-92	193
368	Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials. <b>2017</b> , 92 Suppl 1, 50-62	120
367	Immunotherapy in pancreatic cancer treatment: a new frontier. <b>2017</b> , 10, 168-194	62
366	Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. <b>2017</b> , 162, 479-488	10

365	Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma. <b>2017</b> , 56, 527-533	22
364	Focus on cutaneous and uveal melanoma specificities. <b>2017</b> , 31, 724-743	55
363	A Case Report of Drug-Induced Myopathy Involving Extraocular Muscles after Combination Therapy with Tremelimumab and Durvalumab for Non-Small Cell Lung Cancer. <b>2017</b> , 41, 140-143	20
362	Immunobiology and Immune Based Therapies of Melanoma. <b>2017</b> , 871-890	
361	The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma. <b>2017</b> , 96, e6398	34
360	PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. <b>2017</b> , 23, 3158-3167	301
359	Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells. <b>2017</b> , 30, 467-476	35
358	Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma. <b>2017</b> , 22, 749-753	28
357	Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. <b>2017</b> , 58, 70-76	173
356	Scleroderma Induced by Pembrolizumab: A Case Series. <b>2017</b> , 92, 1158-1163	70
355	Molecular genetic and immunotherapeutic targets in metastatic melanoma. <b>2017</b> , 471, 281-293	14
354	New Developments in Breast Cancer and Their Impact on Daily Practice in Pathology. <b>2017</b> , 141, 490-498	37
353	Cancer immunotherapy: how low-level ionizing radiation can play a key role. <b>2017</b> , 66, 819-832	37
352	Tumors of the Cervix. <b>2017</b> , 618-642	
351	Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update. <b>2016</b> , 6, 1-12	42
350	Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging. <b>2017</b> , 58, 538-546	86
349	Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy. <b>2017</b> , 17, 325-338	24
348	A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma. <b>2017</b> , 23, 351-362	44

347	Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. <b>2017</b> , 5, 17-28	99
346	Intratumor and Intertumor Heterogeneity in Melanoma. <b>2017</b> , 10, 956-975	124
345	Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth. <b>2017</b> , 11, 10135-10146	60
344	Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences. <b>2017</b> , 280, 249-279	110
343	Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors. <b>2017</b> , 7, 13682	22
342	Mechanisms regulating T-cell infiltration and activity in solid tumors. <b>2017</b> , 28, xii18-xii32	175
341	Novel Immunologic Approaches to Melanoma Treatment. <b>2017</b> , 108, 708-720	
340	Advances in immunotherapy in multiple myeloma. <b>2017</b> , 29, 460-466	12
339	The Too Many Faces of PD-L1: A Comprehensive Conformational Analysis Study. <b>2017</b> , 56, 5428-5439	15
338	Identification of a novel component leading to anti-tumor activity besides the major ingredient cordycepin in <i>Cordyceps militaris</i> extract. <b>2017</b> , 1061-1062, 209-219	12
337	Novel Immunologic Approaches to Melanoma Treatment. <b>2017</b> , 108, 708-720	6
336	Clinical significance of novel costimulatory molecule B7-H6 in human breast cancer. <b>2017</b> , 14, 2405-2409	18
335	Targeting Developmental Pathways: The Achilles Heel of Cancer?. <b>2017</b> , 93, 213-223	16
334	Inflammatory regulation of stem-like cells in melanoma. <b>2017</b> , 27, 1-7	0
333	Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. <b>2017</b> , 2, e000203	11
332	IL-21 Therapy Controls Immune Activation and Maintains Antiviral CD8 T Cell Responses in Acute Simian Immunodeficiency Virus Infection. <b>2017</b> , 33, S81-S92	12
331	Cardiotoxicity of immune checkpoint inhibitors. <b>2017</b> , 2, e000247	126
330	Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy. <b>2017</b> , 5, 49	20

329	Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials. <b>2017</b> , 96, e7325	65
328	Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. <b>2017</b> , 6, e1249561	161
327	Basis for molecular diagnostics and immunotherapy for esophageal cancer. <b>2017</b> , 17, 33-45	19
326	Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study. <b>2017</b> , 75, 969-977	25
325	Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy. <b>2017</b> , 37, 129-143	21
324	Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort. <b>2017</b> , 59, 55-61	38
323	Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update. <b>2017</b> , 93 Suppl 1, 147-159	69
322	Case report on the role of radiofrequency-assisted spleen-preserving surgery for splenic metastasis in the era of check-point inhibitors. <b>2017</b> , 96, e9106	5
321	Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy. <b>2016</b> , 5, 59	50
320	Immunobiology of Uveal Melanoma?. <b>2017</b> ,	
319	RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB. <b>2017</b> , 23, 1223-1231	16
318	Uveal Melanoma: Identifying Immunological and Chemotherapeutic Targets to Treat Metastases. <b>2017</b> , 6, 179-185	10
317	Immune-Mediated Therapies for Liver Cancer. <b>2017</b> , 8,	17
316	Anti-Bovine Programmed Death-1 Rat-Bovine Chimeric Antibody for Immunotherapy of Bovine Leukemia Virus Infection in Cattle. <b>2017</b> , 8, 650	13
315	Efficacy of Juzentaihoto for Tumor Immunotherapy in B16 Melanoma Metastasis Model. <b>2017</b> , 2017, 6054706	16
314	Acute Hyperglycemia Associated with Anti-Cancer Medication. <b>2017</b> , 32, 23-29	25
313	Isolated Adrenocorticotrophic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer. <b>2017</b> , 56, 2463-2469	27
312	Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma. <b>2017</b> , 17, 584	5

311	Acute interstitial nephritis after sequential ipilimumab - nivolumab therapy of metastatic melanoma. <b>2017</b> , 5, 57	20
310	Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. <b>2017</b> , 5, 101	174
309	Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update. <b>2017</b> , 98, 2895-2911	41
308	Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab. <b>2017</b> , 8, 41-54	5
307	Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. <b>2017</b> , 6, 373-386	32
306	Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines. <b>2018</b> , 75, 2887-2896	16
305	The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. <b>2018</b> , 25, 1814-1827	30
304	Nanoparticle-Based Phototriggered Cancer Immunotherapy and Its Domino Effect in the Tumor Microenvironment. <b>2018</b> , 19, 1869-1887	45
303	The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: A systematic review and meta-analysis. <b>2018</b> , 59, 328-338	11
302	Long noncoding RNAs in cancer-immunity cycle. <b>2018</b> , 233, 6518-6523	66
301	Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents. <b>2018</b> , 38, 976-987	105
300	Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility. <b>2018</b> , 9, 89-105	10
299	Sustained release of anti-PD-1 peptide for perdurable immunotherapy together with photothermal ablation against primary and distant tumors. <b>2018</b> , 278, 87-99	71
298	Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. <b>2018</b> , 65, e26960	29
297	Skin microbiota-host interactions. <b>2018</b> , 553, 427-436	261
296	Refractory thyroid carcinoma: which systemic treatment to use?. <b>2018</b> , 10, 1758834017752853	13
295	CD8 T Cells and NK Cells: Parallel and Complementary Soldiers of Immunotherapy. <b>2018</b> , 19, 9-20	55
294	Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice. <b>2018</b> , 8, 217	7

293	Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients. <b>2018</b> , 20, 966-974	18
292	Combined inhibition of JAK1,2/Stat3-PD-L1 signaling pathway suppresses the immune escape of castration-resistant prostate cancer to NK cells in hypoxia. <b>2018</b> , 17, 8111-8120	25
291	Tumour-immune dynamics with an immune checkpoint inhibitor. <b>2018</b> , 5, S137-S159	8
290	Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. <b>2018</b> , 18, e183-e198	173
289	A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma. <b>2018</b> , 178, 265-269	32
288	Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine. <b>2018</b> , 14, 159-162	14
287	Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. <b>2018</b> , 38, 325-376	29
286	Technologies for Making New Vaccines. <b>2018</b> , 1283-1304.e7	3
285	Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis. <b>2018</b> , 103, 582-590	32
284	Molecular adjuvants that modulate regulatory T cell function in vaccination: A critical appraisal. <b>2018</b> , 129, 237-250	14
283	Construction of the PD-L1 Promoter-Luciferase Reporter Expressing Vector for Small Molecule Inhibitors Screening. <b>2018</b> , 705-712	
282	PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker. <b>2018</b> , 26, 393-397	7
281	Response to Eruptive keratoacanthomas arising in the setting of lichenoid toxicity after patients on anti-programmed cell death-1 inhibition with nivolumab. <b>2018</b> , 32, e61-e62	2
280	Programmed Death 1 (PD1)-Mediated T-Cell Apoptosis and Cancer Immunotherapy. <b>2018</b> , 695-722	0
279	Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy. <b>2018</b> , 53, 1193-1203	25
278	Cytological diagnosis of metastatic melanoma presenting as an isolated pleural effusion: A case report. <b>2018</b> , 8, 7	
277	Biology of Tumor Associated Macrophages in Diffuse Large B Cell Lymphoma. <b>2018</b> ,	
276	Primary melanoma of the bladder: Case report and review of the literature. <b>2018</b> , 90, 224-226	8

275	Counteracting Resistance to BRAF V600E Mutation in Melanoma Using Dietary Polyphenols. <b>2018</b> , 185-193	
274	Efficacy and safety of PD-1 inhibitors for treating advanced melanoma: a systematic review and meta-analysis. <b>2018</b> , 10, 1293-1302	10
273	Editorial: Immune Checkpoint Molecules and Cancer Immunotherapy. <b>2018</b> , 9, 2878	3
272	Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma. <b>2018</b> , 7, e1461304	36
271	Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin. <b>2018</b> , 8, 14654	2
270	T Cell Calcium Signaling Regulation by the Co-Receptor CD5. <b>2018</b> , 19,	11
269	Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression. <b>2018</b> , 9, 2374	87
268	From Cancer Immunoediting to New Strategies in Cancer Immunotherapy: The Roles of Immune Cells and Mechanics in Oncology. <b>2018</b> , 1092, 113-138	11
267	Programmed Death Ligand 1: A Step Toward Immunoscore for Esophageal Cancer. <b>2018</b> , 106, 1002-1007	8
266	Activating and inhibitory receptors expressed on innate lymphoid cells. <b>2018</b> , 40, 331-341	32
265	Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy. <b>2018</b> , 119, 193-199	7
264	Expression of PD-L1/PD-1 in lymphoepithelioma-like carcinoma of the thymus. <b>2018</b> , 31, 1801-1806	6
263	Immunotherapy treatment: an issue for metabolic response. <b>2018</b> , 62, 140-151	4
262	Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma. <b>2018</b> , 67, 1647-1658	20
261	Checks and Balances in Autoimmune Vasculitis. <b>2018</b> , 9, 315	23
260	Optimizing Tumor Microenvironment for Cancer Immunotherapy: $\beta$ -Glucan-Based Nanoparticles. <b>2018</b> , 9, 341	42
259	Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy. <b>2018</b> , 9, 353	82
258	V $\beta$ V $\gamma$ T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression. <b>2018</b> , 9, 1492	10

257	Immunotherapy Plus Cryotherapy: Potential Augmented Abscopal Effect for Advanced Cancers. <b>2018</b> , 8, 85	43
256	The Emerging Therapeutic Landscape of Advanced Melanoma. <b>2018</b> , 24, 549-558	13
255	Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints. <b>2018</b> , 19,	50
254	Regulation of Memory CD8+ T Cell Differentiation by MicroRNAs. <b>2018</b> , 47, 2187-2198	16
253	Microbial biomarkers for immune checkpoint blockade therapy against cancer. <b>2018</b> , 53, 999-1005	12
252	The Potential Role of circRNA in Tumor Immunity Regulation and Immunotherapy. <b>2018</b> , 9, 9	93
251	Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases. <b>2018</b> , 18, 239	31
250	Targeting the Microenvironment in High Grade Serous Ovarian Cancer. <b>2018</b> , 10,	14
249	SIRS, CARS and MARS in relationship to cancer cachexia and its clinical implications. <b>2018</b> , 26, 54-59	2
248	Lily extracts inhibit the proliferation of gastric carcinoma SGC-7901 cells by affecting cell cycle progression and apoptosis via the upregulation of caspase-3 and Fas proteins, and the downregulation of FasL protein. <b>2018</b> , 16, 1397-1404	1
247	PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease. <b>2018</b> , 15, e1002497	26
246	Potential Successes and Challenges of Targeted Cancer Therapies. <b>2019</b> , 2019,	11
245	T-cell therapies for T-cell lymphoma. <b>2019</b> , 21, 935-942	4
244	Molecular Imaging and Targeted Therapy for Malignant Melanoma. <b>2019</b> , 129-138	
243	Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients. <b>2019</b> , 10, 3070-3078	5
242	Selective Suppression of Cell Growth and Programmed Cell Death-Ligand 1 Expression in HT1080 Fibrosarcoma Cells by Low Molecular Weight Fucoidan Extract. <b>2019</b> , 17,	8
241	Pembrolizumab-associated autoimmune haemolytic anaemia. <b>2019</b> , 12,	3
240	Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers. <b>2019</b> , 144, 102812	5

239	PLGA Nanoparticles Codelivering siRNAs against Programmed Cell Death Protein-1 and Its Ligand Gene for Suppression of Colon Tumor Growth. <b>2019</b> , 16, 4940-4953	19
238	Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells. <b>2019</b> , 7, 231	14
237	Unchecked immunity: a unique case of sequential immune-related adverse events with Pembrolizumab. <b>2019</b> , 7, 247	12
236	Programmed death-ligand 1 and survival in colorectal cancers: A meta-analysis. <b>2019</b> , 34, 356-363	4
235	PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population. <b>2019</b> , 14, 6	17
234	Intestinal microbiota predicts lung cancer patients at risk of immune-related diarrhea. <b>2019</b> , 11, 385-396	22
233	Efficacy and safety of ipilimumab for treating advanced melanoma: A systematic review and meta-analysis. <b>2019</b> , 44, 420-429	9
232	An In Vitro System for Evaluating Molecular Targeted Drugs Using Lung Patient-Derived Tumor Organoids. <b>2019</b> , 8,	18
231	Dual Inhibitors-Loaded Nanotherapeutics that Target Kinase Signaling Pathways Synergize with Immune Checkpoint Inhibitor. <b>2019</b> , 12, 357-373	8
230	Nuclear Medicine in Oncology. <b>2019</b> ,	2
229	Pembrolizumab for cutaneous squamous cell carcinoma: Report of a case of inoperable squamous cell carcinoma with complete response to pembrolizumab complicated by granulomatous inflammation. <b>2019</b> , 5, 491-494	8
228	Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology. <b>2019</b> , 85, 2045-2058	10
227	WD repeat and SOCS box containing protein 2 in the proliferation, cycle progression, and migration of melanoma cells. <b>2019</b> , 116, 108974	6
226	Pembrolizumab for the Treatment of Hepatocellular Carcinoma. <b>2019</b> , 8, 143-154	14
225	Antitumor activity of ginsenoside Rg3 in melanoma through downregulation of the ERK and Akt pathways. <b>2019</b> , 54, 2069-2079	15
224	Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis. <b>2019</b> , 26, 3745-3755	58
223	Managing cardiotoxicity associated with immune checkpoint inhibitors. <b>2019</b> , 5, 6-14	31
222	Long noncoding RNA RMRP promotes proliferation and invasion via targeting miR-1-3p in non-small-cell lung cancer. <b>2019</b> , 120, 15170-15181	26

221	Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions. <b>2019</b> , 10, 910	40
220	Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. <b>2019</b> , 9, 6136	71
219	LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195. <b>2019</b> , 231, 116335	72
218	MHC Class 1 and PDL-1 Status of Primary Tumor and Lymph Node Metastatic Tumor Tissue in Gastric Cancers. <b>2019</b> , 2019, 4785098	11
217	Adapalene suppressed the proliferation of melanoma cells by S-phase arrest and subsequent apoptosis via induction of DNA damage. <b>2019</b> , 851, 174-185	6
216	Divergent SATB1 expression across human life span and tissue compartments. <b>2019</b> , 97, 498-511	11
215	Extracellular Vesicle-Based Therapeutic Targeting of E-Catenin to Modulate Anticancer Immune Responses in Hepatocellular Cancer. <b>2019</b> , 3, 525-541	23
214	Boron-incorporating hemagglutinating virus of Japan envelope (HVJ-E) nanomaterial in boron neutron capture therapy. <b>2019</b> , 20, 291-304	5
213	Immune-Checkpoint Blockade Opposes CD8 T-cell Suppression in Human and Murine Cancer. <b>2019</b> , 7, 510-525	33
212	Treatment of primary nonmetastatic melanoma at high-volume academic facilities is associated with improved long-term patient survival. <b>2019</b> , 80, 979-989	13
211	Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications. <b>2019</b> , 13, 58-69	13
210	Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis. <b>2019</b> , 2, e1160	11
209	PD-L1 expression levels on tumor cells affect their immunosuppressive activity. <b>2019</b> , 18, 5399-5407	28
208	Immune checkpoint inhibitors for unresectable hepatocellular carcinoma. <b>2019</b> ,	78
207	Comparison of the Inflammatory Infiltrates in Tumoral Melanosis, Regressing Nevi, and Regressing Melanoma. <b>2019</b> , 41, 480-487	3
206	Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies. <b>2019</b> , 8, 413-426	16
205	Mass Cytometry Imaging for the Study of Human Diseases-Applications and Data Analysis Strategies. <b>2019</b> , 10, 2657	66
204	Oligosaccharyltransferase: A Gatekeeper of Health and Tumor Progression. <b>2019</b> , 20,	25

203	A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability. <b>2019</b> , 27, 1497-1507	13
202	Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy. <b>2019</b> , 293, 104-112	35
201	Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients. <b>2019</b> , 53,	16
200	Autoimmune Effects of Lung Cancer Immunotherapy Revealed by Data-Driven Analysis on a Nationwide Cohort. <b>2020</b> , 107, 388-396	6
199	Combination of Bacterial-Photothermal Therapy with an Anti-PD-1 Peptide Depot for Enhanced Immunity against Advanced Cancer. <b>2020</b> , 30, 1906623	41
198	NLRC5: new cancer buster?. <b>2020</b> , 47, 2265-2277	7
197	Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy. <b>2020</b> , 12, 413-436	27
196	Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy. <b>2020</b> , 13, 262-274	27
195	CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors. <b>2020</b> , 30, 14-25	11
194	Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor. <b>2020</b> , 35, 1042-1048	11
193	Therapeutic host-directed strategies to improve outcome in tuberculosis. <b>2020</b> , 13, 190-204	55
192	Predicting the clinical outcome of melanoma using an immune-related gene pairs signature. <b>2020</b> , 15, e0240331	6
191	The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy. <b>2020</b> , 21,	20
190	Recent advances of molecular mechanisms of regulating PD-L1 expression in melanoma. <b>2020</b> , 88, 106971	3
189	Human intratumoral therapy: Linking drug properties and tumor transport of drugs in clinical trials. <b>2020</b> , 326, 203-221	10
188	Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. <b>2020</b> , 2020, 9235638	25
187	Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. <b>2020</b> , 8,	14
186	Molecular imaging in immuno-oncology: current status and translational perspectives. <b>2020</b> , 20, 1199-1211	1

185	Diacylglycerol kinase $\beta$ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes. <b>2020</b> , 8,	3
184	Pseudotumor presentation of CMV disease: Diagnostic dilemma and association with immunomodulating therapy. <b>2021</b> , 23, e13531	0
183	Distinct regional ontogeny and activation of tumor associated macrophages in human glioblastoma. <b>2020</b> , 10, 19542	25
182	Mature Dendritic Cells May Promote High-Avidity Tuning of Vaccine T Cell Responses. <b>2020</b> , 11, 584680	3
181	Multifunctional Nanoparticles Boost Cancer Immunotherapy Based on Modulating the Immunosuppressive Tumor Microenvironment. <b>2020</b> , 12, 50734-50747	19
180	Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome. <b>2020</b> , 12,	24
179	Large-Scale Analysis Reveals the Specific Clinical and Immune Features of DGCR5 in Glioma. <b>2020</b> , 13, 7531-7543	6
178	Gated Resonance Energy Transfer (gRET) Controlled by Programmed Death Protein Ligand 1. <b>2020</b> , 10,	9
177	Modeling Immune Checkpoint Inhibitor Efficacy in Syngeneic Mouse Tumors in an Ex Vivo Immuno-Oncology Dynamic Environment. <b>2020</b> , 21,	3
176	Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies. <b>2020</b> , 8, 569219	22
175	The immunoregulatory function of polyphenols: implications in cancer immunity. <b>2020</b> , 85, 108428	6
174	Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. <b>2020</b> , 8,	30
173	Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. <b>2020</b> , 8,	30
172	Nucleic Acid Immunotherapeutics for Cancer. <b>2020</b> , 3, 2838-2849	8
171	Characterization of PD-L1 binding sites by a combined FMO/GRID-DRY approach. <b>2020</b> , 34, 897-914	3
170	PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice. <b>2020</b> , 15, e0228339	12
169	FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls. <b>2020</b> , 50, 518-531	9
168	The relationships between PD-L1 expression, CD8+ TILs and clinico-histomorphological parameters in malignant melanomas. <b>2020</b> , 216, 153071	1

167	The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis. <b>2020</b> , 18, 150	12
166	WITHDRAWN: A novel bifunctional T regulatory cell engaging (BiTE) TGF- $\beta$ /PD-L1 fusion protein with therapeutic potential for autoimmune diseases. <b>2020</b> , 100037	
165	Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer. <b>2020</b> , 16, 87-96	3
164	A novel chalcone derivative has antitumor activity in melanoma by inducing DNA damage through the upregulation of ROS products. <b>2020</b> , 20, 36	8
163	Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancers. <b>2020</b> , 154, 102891	1
162	Emerging strategies to treat rare and intractable subtypes of melanoma. <b>2021</b> , 34, 44-58	8
161	A chemical conjugation of JQ-1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation. <b>2021</b> , 148, 437-447	2
160	Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma. <b>2021</b> , 268, 120579	30
159	Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer. <b>2021</b> , 18, 919-935	2
158	Biomimetic Anti-PD-1 Peptide-Loaded 2D FePSe Nanosheets for Efficient Photothermal and Enhanced Immune Therapy with Multimodal MR/PA/Thermal Imaging. <b>2021</b> , 8, 2003041	26
157	Immunotherapeutic strategies for the treatment of ovarian cancer: current status and future direction. <b>2021</b> , 94, 62-77	4
156	Britannin stabilizes T cell activity and inhibits proliferation and angiogenesis by targeting PD-L1 via abrogation of the crosstalk between Myc and HIF-1 $\beta$ in cancer. <b>2021</b> , 81, 153425	9
155	Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. <b>2021</b> , 112, 305-313	10
154	Chimeric antigen receptor T-cell therapy for melanoma. <b>2021</b> , 17, 209-223	2
153	NECTIN4: A Novel Therapeutic Target for Melanoma. <b>2021</b> , 22,	8
152	Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer. <b>2021</b> , 13,	16
151	Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. <b>2021</b> , 11, 1454-1467	6
150	Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma. <b>2020</b> , 10, 592811	2

149	Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy. <b>2021</b> , 2021, 6661406	26
148	A combinational chemo-immune therapy using an enzyme-sensitive nanoplatform for dual-drug delivery to specific sites by cascade targeting. <b>2021</b> , 7,	23
147	PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme. <b>2021</b> , 11,	1
146	Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation. <b>2021</b> , 213, 113170	11
145	Distinct genomic features across cytolytic subgroups in skin melanoma. <b>2021</b> , 70, 3137-3154	1
144	Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy. <b>2021</b> , 22, 100324	3
143	Molecular Characteristics of Genes and the Immune Microenvironment of a Rare Chest Malignant Tumor (Pulmonary Clear Cell Sarcoma): A Case Report. <b>2021</b> , 11, 664883	1
142	The Mechanisms Leading to Distinct Responses to PD-1/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses. <b>2021</b> , 11, 573547	6
141	Beyond immune checkpoint blockade: emerging immunological strategies. <b>2021</b> , 20, 899-919	39
140	Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study. <b>2021</b> , 2021, 5524685	2
139	CRISPR/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement. <b>2021</b> , 22, 253-284	34
138	Is Relating With M2 Macrophage and Remarkable Malignancy Characters in Low-Grade Glioma. <b>2021</b> , 12, 659659	4
137	Design of PD-1-decorated nanocages targeting tumor-draining lymph node for promoting T cell activation. <b>2021</b> , 333, 328-338	3
136	Age-Associated Changes in Adverse Events Arising From Anti-PD-(L)1 Therapy. <b>2021</b> , 11, 619385	0
135	Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options. <b>2021</b> , 100971	9
134	PD-1 Coexpression Gene Analysis and the Regulatory Network in Endometrial Cancer Based on Bioinformatics Analysis. <b>2021</b> , 2021, 9923434	
133	PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. <b>2021</b> , 22,	16
132	PD-1 Inhibitors Could Improve the Efficacy of Chemotherapy as First-Line Treatment in Biliary Tract Cancers: A Propensity Score Matching Based Analysis. <b>2021</b> , 11, 648068	2

131	Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer. <b>2021</b> , 11, 11427	0
130	Peptide-based assemblies as immune checkpoint inhibitor delivery systems for enhanced immunotherapy. <b>2021</b> , 23, 101063	
129	A Review of Phosphocreatine 3 Kinase [Subtype (PI3K)]and Its Inhibitors in Malignancy. <b>2021</b> , 27, e932772	0
128	Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC. <b>2021</b> , 16, 1211-1223	4
127	Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas. <b>2021</b> , 65,	3
126	Advances in the discovery and development of melanoma drug therapies. <b>2021</b> , 16, 1319-1347	0
125	High-affinity decoy PD-1 mutant screened from an epitope-specific cell library. <b>2021</b> ,	0
124	Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. <b>2021</b> , 40, 949-982	17
123	Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management. <b>2021</b> , 21, 1211-1228	0
122	-Methyladenosine and Rheumatoid Arthritis: A Comprehensive Review. <b>2021</b> , 12, 731842	3
121	Activation of interferon regulatory factor 3 by replication-competent vaccinia viruses improves antitumor efficacy mediated by T cell responses. <b>2021</b> , 22, 399-409	0
120	Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. <b>2021</b> , 14, 101184	2
119	Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma. <b>2021</b> ,	3
118	Anti-drug antibody detection with label-free electrolyte-gated organic field-effect transistors. <b>2021</b> , 57, 367-370	14
117	Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1. <b>2021</b> , 13, 1914359	0
116	Discovery of modulators for the PD-1/PD-L1 interaction by molecular simulation and bioassay.	1
115	Surface engineering of oncolytic adenovirus for a combination of immune checkpoint blockade and virotherapy. <b>2021</b> , 9, 7392-7401	2
114	The TERT copy number gain is sensitive to telomerase inhibitors in human melanoma. <b>2020</b> , 134, 193-205	3

113	Label-free and specific detection of soluble programmed death ligand-1 using a localized surface plasmon resonance biosensor based on excessively tilted fiber gratings. <b>2019</b> , 10, 5136-5148	11
112	In vitro immunotherapy potency assays using real-time cell analysis. <b>2018</b> , 13, e0193498	53
111	Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis. <b>2020</b> , 15, 447-456	3
110	Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model. <b>2016</b> , 7, 76891-76901	8
109	Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide. <b>2017</b> , 8, 50342-50358	20
108	PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma. <b>2017</b> , 8, 54722-54734	30
107	Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. <b>2017</b> , 8, 97671-97682	173
106	Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection. <b>2017</b> , 8, 82399-82414	15
105	Sustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab. <b>2019</b> , 10, 3302-3311	4
104	SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells. <b>2016</b> , 7, 30166-77	24
103	Novel implications in the treatment of hepatocellular carcinoma. <b>2017</b> , 30, 23-32	23
102	Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation. <b>2019</b> , 33, 15-21	25
101	Integrating Bioinformatics Strategies in Cancer Immunotherapy: Current and Future Perspectives. <b>2020</b> , 23, 687-698	3
100	Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide. <b>2017</b> , 37, 3413-3421	4
99	Immunoterapia z użyciem przeciwciał monoklonalnych ukierunkowanych na szlak PD-1/PD-L1 w chorobach nowotworowych. <b>2018</b> , 49, 207-227	1
98	Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents. <b>2020</b> , 8, 9-22	4
97	Nanobodies targeting immune checkpoint molecules for tumor immunotherapy and immunoimaging (Review). <b>2021</b> , 47, 444-454	5
96	Update on uveal melanoma: Translational research from biology to clinical practice (Review). <b>2020</b> , 57, 1262-1279	10

95	Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials. <b>2015</b> , 7, 1-11	7
94	Second Primary Cancer Risk among Kidney Cancer Patients in Korea: A Population-Based Cohort Study. <b>2018</b> , 50, 293-301	12
93	The detailed distribution of T cell subpopulations in immune-stable renal allograft recipients: a single center study. <b>2019</b> , 7, e6417	6
92	Immunogenomic Analyses of the Prognostic Predictive Model for Patients With Renal Cancer. <b>2021</b> , 12, 762120	1
91	[In Process Citation]. <b>2015</b> , 135, 1545	
90	Patient Selection and Monitoring for Immunotherapies: Challenges for Immune Checkpoint Antibody and Cell Therapies. <b>2015</b> , 85-101	
89	Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance. <b>2017</b> , 37, 225-235	6
88	The Story of Adjuvants to Boost the Performance of Cryoablation. <b>2017</b> , 385-397	
87	Neue Arzneimittel lassen hoffen. <b>2018</b> , 66, 604-617	
86	INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS. <b>2019</b> , 21, 59-68	1
85	Cutaneous malignant melanoma and targeted therapy based on the biomarkers. <b>2019</b> , 40, 325	
84	Predicting treatment outcome and enhancing immunotherapy with anti-PDL1 gold nanoparticles. <b>2019</b> ,	
83	Pembrolizumab and Nivolumab in the treatment of Non-small cell lung cancer (NSCLC).. <b>2019</b> , 4, 942-947	
82	Immature dendritic cells promote high-avidity tuning of vaccine T cell response.	
81	Proteomic Implications of Tumoral Infiltrating Lymphocytes in Melanoma: PD-L1, CD4 and CD8 - Short Review. <b>2020</b> , 26, 117-121	
80	Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review. <b>2020</b> , 20, 720-727	4
79	Immunotherapy for Stage III NSCLC: Durvalumab and Beyond. <b>2021</b> , 12, 123-131	1
78	Metabolische und endokrine Toxizität antineoplastischer Substanzen. <b>2020</b> , 1-9	

77	CD73-positive extracellular vesicles promote glioblastoma immunosuppression by inhibiting T-cell clonal expansion. <b>2021</b> , 12, 1065	1
76	PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab. <b>2016</b> , 6, 2117-2128	18
75	Therapeutic targeting of immune checkpoints with small molecule inhibitors. <b>2019</b> , 11, 529-541	8
74	TLR3 regulates PD-L1 expression in human cytomegalovirus infected glioblastoma. <b>2018</b> , 11, 5318-5326	2
73	Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer. <b>2020</b> , 10, 2878-2894	3
72	Localized delivery of immunotherapy via implantable scaffolds for breast cancer treatment. <b>2021</b> , 341, 399-413	3
71	A Darwinian perspective on tumor immune evasion.. <b>2021</b> , 1877, 188671	0
70	Pigmented skin neoplasm in a child: Bmplex case report and review of the literature. <b>2020</b> , 12, 16-25	1
69	Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases.. <b>2021</b> , 12, 790963	3
68	Solid Tumours and Update on Modern Medical Oncology Interventions. <b>2022</b> , 23-38	
67	In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-1/PD-L1 interaction.. <b>2022</b> , 12, 303	0
66	Development of Monoclonal B-cell Lymphocytosis Shortly After Treatment with Nivolumab and Subsequent Progression to Chronic Lymphocytic Leukemia.. <b>2022</b> , 10781552221074025	
65	Lirilumab and Avelumab Enhance Anti-HPV+ Cervical Cancer Activity of Natural Killer Cells Vav1-Dependent NF- $\kappa$ B Disinhibition.. <b>2022</b> , 12, 747482	0
64	Establishment of operational tolerance to sustain antitumor immunotherapy.. <b>2022</b> ,	
63	Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas.. <b>2022</b> , 12,	0
62	T cell receptor (TCR) signaling in health and disease.. <b>2021</b> , 6, 412	9
61	Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model.	
60	First experiences with the use of targeted and immunotherapy in the treatment of cutaneous melanoma: A single centre experience. <b>2022</b> , 53, 29-35	

59	Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice.. <b>2022</b> , 43, 2339	1
58	Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions.. <b>2022</b> , 10,	1
57	Nectin-4: a Novel Therapeutic Target for Skin Cancers.. <b>2022</b> , 23, 578	1
56	PDL1 positivity rate between triple negative and non-luminal Her2+ cases. <b>2022</b> , 18,	
55	Exploring the Role of Transglutaminase in Patients with Glioblastoma: Current Perspectives.. <b>2022</b> , 15, 277-290	1
54	Deep Downregulation of PD-L1 by Caged Peptide-Conjugated AIEgen/miR-140 Nanoparticles for Enhanced Immunotherapy.	
53	In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy.. <b>2022</b> , 14, 100238	1
52	A Pan-Cancer Bioinformatic Analysis of RAD51 Regarding the Values for Diagnosis, Prognosis, and Therapeutic Prediction.. <b>2022</b> , 12, 858756	2
51	Deep Downregulation of PD-L1 by Caged Peptide-Conjugated AIEgen/miR-140 Nanoparticles for Enhanced Immunotherapy.. <b>2022</b> ,	6
50	Ferroptosis-related gene SLC1A5 is a novel prognostic biomarker and correlates with immune infiltrates in stomach adenocarcinoma.. <b>2022</b> , 22, 124	1
49	CircFOXK2 enhances tumorigenesis and immune evasion in non-small cell lung cancer by miR-485-5p/PD-L1 axis.. <b>2022</b> , 33,	
48	Case Report: Complete Remission With Anti-PD-1 and Anti-VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma.. <b>2022</b> , 12, 809068	2
47	Prognostic model based on six PD-1 expression and immune infiltration-associated genes predicts survival in breast cancer.. <b>2022</b> , 1	1
46	Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers.. <b>2022</b> , 7, 100419	1
45	A comprehensive bioinformatic analysis of cyclin-dependent kinase 2 (CDK2) in glioma.. <b>2022</b> , 822, 146325	2
44	Tri-component programmable nanoregulator with Three-pronged penetration boosts immunotherapy of Triple-Negative breast cancer. <b>2022</b> , 439, 135712	2
43	Tilsetolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma.. <b>2021</b> , 1-13	0
42	Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.. <b>2022</b> , 13, 844736	0

41	The role of cell-penetrating peptides in potential anti-cancer therapy.. <b>2022</b> , 12, e822	3
40	Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. <b>2022</b> , 10, 1181	1
39	Sensing Soluble Immune Checkpoint Molecules and Disease-Relevant Cytokines in Cancer: A Novel Paradigm in Disease Diagnosis and Monitoring. <b>2022</b> , 3,	0
38	Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model.	1
37	Efficacy and Safety of Camrelizumab in Combination with Docetaxel + S-1 Sequenced by Camrelizumab + S-1 for Stage III (PD-1+/MSI-H/EBV+/dMMR) Gastric Cancer: Study Protocol for a Single-Center, Prospective, Open-Label, Single-Arm Trial. 9,	1
36	PD-L1 in gestational trophoblastic disease: an antibody evaluation.	
35	A novel strategy to fuel cancer immunotherapy: targeting glucose metabolism to remodel the tumor microenvironment. 12,	0
34	A B7-CD28 Family-Based Signature Demonstrates Significantly Different Prognosis and Immunological Characteristics in Diffuse Gliomas. 9,	
33	Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer. <b>2022</b> , 1-20	
32	Clinical and Biological Activity of Chemo-immunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium.	
31	Immunotherapeutic Strategies for Head and Neck Squamous Cell Carcinoma (HNSCC): Current Perspectives and Future Prospects. <b>2022</b> , 10, 1272	
30	Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction. <b>2022</b> , 73, 117001	2
29	A cell-laden hydrogel as prophylactic vaccine and anti-PD-L1 amplifier against autologous tumors. <b>2022</b> , 351, 231-244	0
28	The Interface of Cancer, Their Microenvironment and Nanotechnology. <b>2022</b> , 24, 371-411	0
27	Primary melanoma of the bladder: case report and review of the literature. <b>2022</b> , 20,	0
26	Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment. <b>2022</b> , 14, 2076	2
25	Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance. 12,	0
24	NOX4 has the potential to be a biomarker associated with colon cancer ferroptosis and immune infiltration based on bioinformatics analysis. 12,	0

- 23 Vesicular stomatitis virus sensitizes immunologically cold tumors to checkpoint blockade by inducing pyroptosis. **2022**, 1868, 166538 ○
- 22 Decoding the Impact of Genetic Variants in Gastric Cancer Patients Based on High-Dimensional Copy Number Variation Data Using Next-Generation Knowledge Discovery Methods. **2022**, 12, 10053 ○
- 21 Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. 12, ○
- 20 Neuro-ophthalmic complications of immune checkpoint inhibitor therapy: Current status and future directions. 2, ○
- 19 Antitumor efficacy of multi-target <i>in situ</i> vaccinations with CpG oligodeoxynucleotides, anti-OX40, anti-PD1 antibodies, and aptamers. **2022**, 37, 1 ○
- 18 mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53flox/+LSL-KrasG12D/+Pdx-1-Cre murine models. **2023**, 554, 216020 ○
- 17 Peptide self-assembled nanomedicine induces antitumor immunity by blocking the PD-1/PD-L1 axis. 9, ○
- 16 Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art. 13, ○
- 15 Artificial Intelligence and Advanced Melanoma: Treatment Management Implications. **2022**, 11, 3965 1
- 14 Adaptive immune response in pathogenesis and treatment of head and neck squamous cell carcinoma: the influence of immunosuppression factors and gender. **2022**, 12, 114-126 ○
- 13 Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. **2022**, 100868 ○
- 12 Immune Checkpoint Inhibitors and Reproductive Failures. **2023**, 103799 ○
- 11 Identification of a novel immune-related gene signature for prognosis and the tumor microenvironment in patients with uveal melanoma combining single-cell and bulk sequencing data. 14, ○
- 10 Association of Computed Tomography Measures of Muscle and Adipose Tissue and Progressive Changes throughout Treatment with Clinical Endpoints in Patients with Advanced Lung Cancer Treated with Immune Checkpoint Inhibitors. **2023**, 15, 1382 ○
- 9 Widespread vitiligo and poliosis following ipilimumabnivolumab combination therapy. 107815522311544 ○
- 8 Comparison of tumor-derived total RNA and cell lysate on antitumor immune activity. **2023**, 160, 114377 ○
- 7 Immunotherapy for Cutaneous Melanoma. **2023**, 1-35 ○
- 6 Simultaneous Knockdown of Immune Suppressive Markers by Tumor Microenvironment-Responsive Multifaceted Prodrug Nanomedicine. **2023**, 15, 12864-12881 ○

- 5 Acral Melanoma Is Infiltrated with cDC1s and Functional Exhausted CD8 T Cells Similar to the Cutaneous Melanoma of Sun-Exposed Skin. **2023**, 24, 4786
- 4 Diversity of immune checkpoints in cancer immunotherapy. 14,
- 3 Positive direct antiglobulin tests in cancer patients on immune checkpoint inhibitors: A case series from India. **2023**,
- 2 HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models. **2023**, 13,
- 1 Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors. **2023**, 67,